Human Metabolome Technologies Inc
TSE:6090
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Digitalist Group Oyj
OMXH:DIGIGR
|
FI |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| JP |
|
Human Metabolome Technologies Inc
TSE:6090
|
4B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
198.4B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.4B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
315.4B CNY |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.5B CHF |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
32.5B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.3B USD |
Loading...
|
Market Distribution
| Min | -179.8% |
| 30th Percentile | 21.8% |
| Median | 30.6% |
| 70th Percentile | 42.3% |
| Max | 18 197.9% |
Other Profitability Ratios
Human Metabolome Technologies Inc
Glance View
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. The company is headquartered in Tsuruoka-Shi, Yamagata-Ken and currently employs 69 full-time employees. The company went IPO on 2013-12-24. The firm operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Human Metabolome Technologies Inc is 60.5%, which is below its 3-year median of 64.3%.
Over the last 3 years, Human Metabolome Technologies Inc’s Gross Margin has decreased from 66.2% to 60.5%. During this period, it reached a low of 60.5% on Jan 1, 2026 and a high of 66.2% on Dec 31, 2022.
